Literature DB >> 9727784

Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis.

M L Plit1, R Anderson, C E Van Rensburg, L Page-Shipp, J A Blott, J L Fresen, C Feldman.   

Abstract

Patients who have completed a treatment for severe pulmonary tuberculosis (TB) are often left with severe respiratory disability. There have been few prospective studies assessing the effect of treatment on lung function in such patients. The influence of antimicrobial chemotherapy on lung function was investigated over a six month period in patients with newly diagnosed pulmonary TB to test the hypothesis that treatment improves lung function, as well as to identify factors that may influence lung function outcome. Seventy-six patients were recruited into the study, of whom 74 completed the treatment programme. Forty-two were current smokers and 13 seropositive for the human immunodeficiency virus. Improvement in lung function occurred in 54% of patients, but residual airflow limitation or a restrictive pattern was evident in 28% and 24% of patients, respectively. The extent of lung infiltration (radiographic score) both at the outset and after chemotherapy was significantly and negatively related to forced expiratory volume in one second (FEV1) (% pred) (r=-0.41, and r=-0.46, respectively). The post-treatment serum C-reactive protein and alpha1-protease inhibitor levels were negatively associated with FEV1 (% pred) (r=-0.30 and r=-0.35, respectively). These findings demonstrate that, while antimicrobial chemotherapy may lead to improved lung function in patients with pulmonary tuberculosis, a large proportion of patients has residual impairment. The most significant factor influencing post-treatment lung function status, as measured by forced expiratory volume in one second (% predicted), is the pretreatment and post-treatment radiographic score, which acts as a marker of the extent of pulmonary parenchymal involvement in tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9727784     DOI: 10.1183/09031936.98.12020351

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  51 in total

Review 1.  Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD.

Authors:  R N van Zyl Smit; M Pai; W W Yew; C C Leung; A Zumla; E D Bateman; K Dheda
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

Review 2.  The convergence of the global smoking, COPD, tuberculosis, HIV, and respiratory infection epidemics.

Authors:  Richard N van Zyl-Smit; Laurence Brunet; Madhukar Pai; Wing-Wai Yew
Journal:  Infect Dis Clin North Am       Date:  2010-09       Impact factor: 5.982

3.  Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.

Authors:  Selvakumar Subbian; Liana Tsenova; Paul O'Brien; Guibin Yang; Mi-Sun Koo; Blas Peixoto; Dorothy Fallows; Jerome B Zeldis; George Muller; Gilla Kaplan
Journal:  Am J Pathol       Date:  2011-05-07       Impact factor: 4.307

4.  Factors associated with abnormal spirometry among HIV-infected individuals.

Authors:  M Bradley Drummond; Laurence Huang; Philip T Diaz; Gregory D Kirk; Eric C Kleerup; Alison Morris; William Rom; Michael D Weiden; Enxu Zhao; Bruce Thompson; Kristina Crothers
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

5.  Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.

Authors:  A Jayakumar; E Vittinghoff; M R Segal; W R MacKenzie; J L Johnson; P Gitta; J Saukkonen; J Anderson; M Weiner; M Engle; C Yoon; M Kato-Maeda; P Nahid
Journal:  Tuberculosis (Edinb)       Date:  2015-05-09       Impact factor: 3.131

6.  Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment.

Authors:  E Hnizdo; T Singh; G Churchyard
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

7.  Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis.

Authors:  Shruthi Ravimohan; Sara C Auld; Pholo Maenetje; Nelly Ratsela; Mandla Mlotshwa; Itai Ncube; Jonathan P Smith; Mboyo-Di-Tamba Vangu; Modulakgotla Sebe; Andrew Kossenkov; Drew Weissman; Robert S Wallis; Gavin Churchyard; Hardy Kornfeld; Gregory P Bisson
Journal:  Clin Infect Dis       Date:  2020-04-15       Impact factor: 9.079

8.  Waiting to inhale: An exploratory review of conditions that may predispose to pulmonary hypertension and right heart failure in persons exposed to household air pollution in low- and middle-income countries.

Authors:  Gerald S Bloomfield; David K Lagat; O Constantine Akwanalo; E Jane Carter; Njira Lugogo; Rajesh Vedanthan; Eric J Velazquez; Sylvester Kimaiyo; Charles B Sherman
Journal:  Glob Heart       Date:  2012-09-01

Review 9.  Assessment of treatment response in tuberculosis.

Authors:  Neesha Rockwood; Elsa du Bruyn; Thomas Morris; Robert J Wilkinson
Journal:  Expert Rev Respir Med       Date:  2016-03-31       Impact factor: 3.772

10.  The association between airflow obstruction and radiologic change by tuberculosis.

Authors:  Yong Il Hwang; Joo Hee Kim; Chang Youl Lee; Sunghoon Park; Yong Bum Park; Seung Hun Jang; Cheol Hong Kim; Tae Rim Shin; Sang Myun Park; Yun Su Sim; Dong-Gyu Kim; Myung-Goo Lee; In-Gyu Hyun; Ki-Suck Jung
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.